Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Stage IV Lung Cancer AJCC v8
Interventions: DRUG: Atezolizumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|BIOLOGICAL: PD1 Inhibitor
Sponsor: Fred Hutchinson Cancer Center
Collaborators: SignalOne Bio, Inc.